Mazdutide is an investigational unimolecular dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), developed as an analog of oxyntomodulin. It combines GLP-1R and GCGR receptor activation mechanisms, making it a subject of ongoing preclinical and clinical research into dual-receptor incretin biology. This product is supplied as a research-grade lyophilized powder synthesized under strict quality controls with full analytical documentation. For Research Use Only. Not for human use.
Key Scientific Attributes
- High-purity Mazdutide (≥98% by HPLC/MS, acetate salt form)
- Verified 39-amino-acid sequence based on oxyntomodulin scaffold with modifications for dual GLP-1R/GCGR agonism
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, and receptor-binding assays (GLP-1R/GCGR EC50)
- Manufactured in GMP-aligned, ISO-compliant facilities
- Suitable for dual-agonist receptor signaling pathway studies and incretin biology research
Research-Referenced Attributes (Based on published preclinical and clinical literature; not therapeutic claims.)
- Dual GLP-1R/GCGR receptor activation profile studied in published Phase 2 and Phase 3 trials (GLORY program, DREAMS program); see peer-reviewed sources for full data
- Receptor pharmacology data available in published literature, including studies in cardiometabolic, incretin, and hepatic fat metabolism research models
- Investigated in NAFLD/MASH models and neurological research contexts involving glutamate receptor pathways
- Favorable in vitro tolerability profile reported across published preclinical literature
Why Researchers Choose Nationwide Peptides Mazdutide
- Exact clinical-sequence match to IBI362/LY3305677 with verified dual-receptor binding affinity
- High potency for GLP-1R/GCGR in vitro studies among research-grade suppliers
- Transparent analytical data (HPLC ≥98%, MS confirmation)
- Competitive research pricing with bulk options available
